As per the deal, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share, for a total consideration of $188.24 per Allergan Share.
The deal, which is expected to close early next year, represents approximately 45% premium over Allergan’s closing price on Monday.
Abbvie shares plunged 7.5% immediately following the announcement, while Allergan stock soared 28.5%.
AbbVie expects annual pre-tax synergies and other cost reductions from the deal of at least $2 billion in the third year while leaving investments in key growth franchises untouched.
Immediately following the deal, AbbVie shareholders are expected to have approximately 83% stake in AbbVie on a fully diluted basis, and the rest with Allergan shareholders.
Allergan CEO Brent Saunders said, “With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash flows, our combined company will have the opportunity to make even bigger contributions to global health than either can alone.”
The deal comes at a time the North Chicago, Illinois-based bio-pharmaceutical company is fast approaching the closure of its patent protection for its flagship product Humira. The immunology drug accounts for more than half of Abbvie’s total revenue.
With the acquisition, AbbVie could be looking to establish a strong base in the beauty drugs market.
This is the second massive deal to be announced in the bio-pharma segment this year. On January 3, Bristol-Myers Squibb (NYSE: BMY) said it would acquire its peer Celgene (NASDAQ: CELG) in a $74-billion cash-and-stock deal. However, this deal has been delayed, first due to shareholder opposition, and then due to antitrust concerns.
The Coca-Cola Company (NYSE: KO) reported first-quarter 2021 financial results before the regular market hours on Monday. The beverage manufacturer reported fourth-quarter revenue of $9 billion, up 5% year-over-year. The
The market rally gathered pace this week amid impressive quarterly results, led by the banking sector, and positive economic data. Leading stock indexes continued their winning streak, with S&P 500
Leading Wall Street banks recorded robust earnings in the early months of fiscal 2021 with the results benefiting from the release of credit loss reserves, in most cases. Taking advantage